Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML

NCT07486479 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

204

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia (AML)

Interventions

DRUG: Mitoxantrone Hydrochloride Liposome
DRUG: Venetoclax
DRUG: Azacitidine
DRUG: Idarubicin
DRUG: Cytarabine

Sponsor

The First Affiliated Hospital of Soochow University

Collaborators

[object Object]